Drug Profile
Mopidamol
Alternative Names: OLX 102; RA 233; RapentonLatest Information Update: 27 Mar 2002
Price :
$50
*
At a glance
- Originator Boehringer Ingelheim Pharma KG
- Developer Antigenics; Boehringer Ingelheim Pharma KG
- Class Pyrimidines; Small molecules
- Mechanism of Action Immunostimulants; Phosphoric diester hydrolase inhibitors; Thromboxane receptor antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Marketed Cancer metastases
- Discontinued Non-small cell lung cancer; Ovarian cancer; Thrombosis
Most Recent Events
- 27 Mar 2002 Launched for Cancer metastases in Germany (IV)
- 07 Feb 2001 No-Development-Reported for Cancer metastases in Germany (IV)
- 12 Jan 2000 Discontinued-Clinical for Ovarian cancer in Finland (IV)